Status: Not yet recruiting
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus
This is a phase I clinical study to evaluate the safety , pharmacokinetic profile, and preliminary efficacy of F01 in patients with moderate-to-severe refractory systemic lupus erythematosus.
Participants needed: 50
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Shanghai Simnova Biotechnology Co.,Ltd.Updated: Jun 21, 2024Locations: 1
Eligibility criteria
Age ≥18 and ≤65 years old, gender unlimited. [+14]
Known allergies, hypersensitivity, intolerance, or contraindications to F01 or a... [+23]